MONTREAL, QUEBEC--(Marketwire - March 22, 2013) - IBEX Technologies Inc. (TSX VENTURE:IBT) today announces the departure of Nancy Bisson as Director of Finance.

Nancy left IBEX in order to pursue a new venture. IBEX would like to thank her for her work with IBEX in the last five years and wishes her good luck in her new career.

Effective immediately, and until the appointment of a new Director of Finance, Paul Baehr, President and CEO will act as interim Director of Finance, in addition to his current duties.

ABOUT IBEX

The Company, through its wholly owned subsidiaries, IBEX Pharmaceuticals Inc. (Montreal) and Bio- Research Products Inc. (North Liberty, IA), manufactures and markets a series of proprietary enzymes for use in diagnostic tests and research. IBEX also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research.

For more information, please visit the Company's website at [ www.ibex.ca ].

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements.